Sabby Management’s AstraZeneca AZN Stock Holding History

Sabby Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-182,500	Closed	-$18.2M	–	163
2020 Q4	$18.2M	Buy	182,500 +108,527	+147%	+$11.5M	3.5%	9
2020 Q3	$8.11M	Buy	73,973 +58,313	+372%	+$6.49M	1.21%	17
2020 Q2	$1.66M	Buy	+15,660	New	+$1.62M	0.33%	38
2018 Q3	–	Sell	-34,232	Closed	-$2.59M	–	129
2018 Q2	$2.4M	Buy	+34,232	New	+$2.46M	0.37%	39
2015 Q1	–	Sell	-192,055	Closed	-$13.5K	–	296
2014 Q4	$13.5K	Sell	192,055 -23,268	-11%	-$1.67M	0.43%	32
2014 Q3	$21	Buy	215,323 +159,048	+283%	+$11.6M	﹤0.01%	250
2014 Q2	$4.18M	Buy	+56,275	New	+$4.07M	0.18%	70
2013 Q4	–	Sell	-26,585	Closed	-$1.38M	–	222
2013 Q3	$1.38M	Buy	+26,585	New	+$1.34M	0.09%	108

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's AZN Position: Q1 2021 in Review

Sabby Management sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 182,500 shares — an estimated $18.2M sold.

Sabby Management first reported a position in AZN in Q3 2013 and held it in 8 quarters. The position peaked at $18.2M in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Sabby Management reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 182,500 AstraZeneca shares in Q1 2021, an estimated $18.2M.
Sabby Management first reported a position in AstraZeneca in Q3 2013 and held it in 8 quarters.
Sabby Management's AstraZeneca position peaked at $18.2M in Q4 2020.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.